Skip to main content
Hikal Ltd. logo

Hikal Ltd. — Investor Relations & Filings

Ticker · HIKAL ISIN · INE475B01022 LEI · 335800OLTGHHYZWTF859 BSE.NS Manufacturing
Open in API
Filings indexed 715 across all filing types
Latest filing 2023-05-29 Interim / Quarterly Rep…
Country IN India
Listing BSE.NS HIKAL

About Hikal Ltd.

https://www.hikal.com

Hikal Ltd. provides solutions across the life sciences value chain, specializing in the development and manufacturing of active ingredients, intermediates, and formulations. The company operates through two primary business segments: Pharmaceuticals and Crop Protection. In the pharmaceutical division, it focuses on the production of Active Pharmaceutical Ingredients (APIs) and advanced intermediates for various therapeutic areas. The crop protection segment involves the contract manufacturing of pesticides, herbicides, and fungicides for global agrochemical leaders. Hikal offers comprehensive Contract Research and Manufacturing Services (CRAMS), leveraging its research and development capabilities to support clients from early-stage development to commercial-scale production. Its facilities adhere to international quality standards, maintaining a strong track record of regulatory compliance with global health authorities.

Recent filings

Filing Released Lang Actions
Financial Result Updates
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement dated May 29, 2023, from Hikal Limited addressed to stock exchanges, reporting the outcome of a Board Meeting pursuant to SEBI regulations. It includes approval and recording of audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2023, along with the auditor's report and declaration of unmodified opinion. The document also discusses dividend recommendations and trading window reopening. The presence of the full auditor's report, detailed financial results tables, and management responsibilities indicates this is the actual audited financial results report, not just an announcement or summary. The document length (15,000 characters) and content confirm it is a comprehensive financial report. Therefore, this filing is best classified as an Interim / Quarterly Report (IR) because it contains quarterly and year-end audited financial results but is not a full annual report (10-K). The document is not a mere announcement or certification, so it is not RPA or RNS. The detailed auditor's report and financial data confirm it is a substantive financial report for a period shorter than a full fiscal year (quarter and year-end results).
2023-05-29 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 95% confidence The document is a notification about an upcoming earnings conference call scheduled for May 29, 2023, to discuss the financial and operational performance for the quarter and financial year ended March 31, 2023. It includes details such as dial-in numbers, participants, and RSVP contacts. The document does not contain any financial data or results itself, but rather serves as an announcement of the call where such information will be discussed. Therefore, it is not an Earnings Release (ER) or an Interim/Quarterly Report (IR), but a notice about the conference call. This fits the definition of a Call Transcript (CT) category, as it relates to the earnings conference call event, although the transcript itself is not included, the document is clearly about the call. Given the nature of the document as an invitation/intimation for the earnings call, the best fitting category is Call Transcript (CT).
2023-05-26 English
Board Meeting — HIKAL LIMITED has informed the Exchange about Board Meeting to be held on 29-May-2023 to consider and approve the Yearly Audited Financial results of the Company for the period ended…
Regulatory Filings
2023-05-22 English
Board Meeting — Financial Results/Dividend
Regulatory Filings
2023-05-22 English
Disclosure under SEBI Takeover Regulations
Regulatory Filings
2023-05-19 English
Updates
Regulatory Filings Classification · 95% confidence The document is a detailed response from Hikal Limited to a proxy advisory firm's report titled "Shareholder Battle Impacting Corporate Performance." It addresses allegations about the impact of a legal dispute between promoter families on the company's performance, management bandwidth, board composition, and remuneration. The content is a rebuttal and clarification rather than a financial report or announcement of financial results. It does not contain financial statements, earnings highlights, or regulatory certifications. It is also not a proxy solicitation, voting result, or management change announcement. The document is a regulatory communication responding to external claims, aiming to clarify corporate governance and operational matters. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-05-18 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.